GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France

About this update from Gensight Biologics Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/a84a79b63818e29c72a2b5fa7056d556"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kccUbnGfJaInxN0I9RgrmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a84a79b63818e29c72a2b5fa7056d556","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"French medicines agency ANSM and Ethics Committee authorize the dose-ranging study investigating two doses of candidate product for the treatment of ND4-LHON.","length":158,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approval of the study protocol will support the ongoing review of the named patient early access program (AAC) in France.","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Phase II study is expected to start in January 2026.","length":56,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":335,"olType":false},{"type":"text","content":"PARIS, December 02, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has authorized the dose-ranging study REVISE, which will investigate the efficacy and safety of two dose levels of the Company’s candidate gene therapy GS010/LUMEVOQ®.","length":539,"tagName":"p"},{"type":"text","content":"The study had been requested by the agency during discussions with the Company about a named patient early access program for the candidate product, which is in clinical development for the treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by a mutated ND4 mitochondrial gene.1 Regulatory approval was granted after the ANSM assessed the GS010/LUMEVOQ® quality dossier and clinical aspects of REVISE. The study also received approval from the Ethics Committee. The ...

More updates from Gensight Biologics Sa